Philips Healthcare said it has collaborated with radiopharmaceutical developer FluoroPharma Medical on a phase II clinical trial for FluoroPharma's CardioPET radiopharmaceutical.
FluoroPharma collaborated with Philips on image management, ensuring that uniform standards were applied to data from the vendor's molecular imaging systems, according to the companies. Conducted in Belgium, the phase II study found no deaths and no serious adverse events from the use of CardioPET to identify coronary artery disease in patients with positive clinically indicated SPECT scans. The CardioPET images also demonstrated evidence of coronary artery disease, with confirmation by SPECT and angiography, according to the firms.
The study was presented at this week's European Association of Nuclear Medicine (EANM) annual congress in Barcelona, Spain. In a statement, FluoroPharma President and CEO Thomas Tulip, PhD, said the firm looks forward to working with Philips to optimize image quality and potentially design new approaches tailored to the specific features of CardioPET.
